J. Culberson

发表

Somatotopic organization of single primary afferent axon projections to cat spinal cord dorsal horn

L. Pubols, P. Brown, R. Millecchia, 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.

Design and biological activity of (S)-4-(5-([1-(3-chlorobenzyl)-2-oxopyrrolidin-3-ylamino]methyl)imidazol-1-ylmethyl)benzonitrile, a 3-aminopyrrolidinone farnesyltransferase inhibitor with excellent cell potency.

A. D. Rodrigues, E S Walsh, J B Gibbs, 2001, Journal of medicinal chemistry.

Analogs of MK-499 are differentially affected by a mutation in the S6 domain of the hERG K+ channel.

R. Spencer, L. Kiss, J. Culberson, 2009, Biochemical pharmacology.

Biochemical and structural characterization of a novel class of inhibitors of the type 1 insulin-like growth factor and insulin receptor kinases.

S. Stirdivant, L. Kuo, P. Darke, 2005, Biochemistry.

Novel oxazolidinone calcitonin gene-related peptide (CGRP) receptor antagonists for the acute treatment of migraine.

H. Selnick, M. Fraley, D. Gauvreau, 2015, Bioorganic & medicinal chemistry letters.

Non-thiol 3-aminomethylbenzamide inhibitors of farnesyl-protein transferase.

T. Ciccarone, N. Kohl, J. Gibbs, 1999, Bioorganic & medicinal chemistry letters.

Cutaneous Stimuli Dorsal Horn Spatial Representation of Simple

R. Poppele, E. Zimlichman, G. Bosco, 2015 .

1-(((7,7-Dimethyl-2(S)-(2(S)-amino-4-(methylsulfonyl)butyramido) bicyclo(2.2.1)heptan-1(S)-yl)methyl)sulfonyl)-4-(2-methylphenyl) piperazine (L-368,899): An Orally Bioavailable, Non-Peptide Oxytocin Antagonist with Potential Utility for Managing Preterm Labor.

B. E. Evans, M. Bock, R. Freidinger, 1994 .

1-((7,7-Dimethyl-2(S)-(2(S)-amino-4-(methylsulfonyl)butyramido)bicyclo [2.2.1]-heptan-1(S)-yl)methyl)sulfonyl)-4-(2-methylphenyl)piperaz ine (L-368,899): an orally bioavailable, non-peptide oxytocin antagonist with potential utility for managing preterm labor.

B. E. Evans, M. Bock, P. Anderson, 1994, Journal of medicinal chemistry.

Imidazole-containing diarylether and diarylsulfone inhibitors of farnesyl-protein transferase.

N. Kohl, R. Lobell, J. Gibbs, 1999, Bioorganic & medicinal chemistry letters.

Evaluation of amino acid-based linkers in potent macrocyclic inhibitors of farnesyl-protein transferase.

J. Davide, N. Kohl, R. Lobell, 2001, Bioorganic & medicinal chemistry letters.

MegaSyn: Integrating Generative Molecular Design, Automated Analog Designer, and Synthetic Viability Prediction

Sean Ekins, Fabio Urbina, Christopher Lowden, 2021, ACS omega.

Random Forest: A Classification and Regression Tool for Compound Classification and QSAR Modeling

Robert P. Sheridan, Andy Liaw, Vladimir Svetnik, 2003, J. Chem. Inf. Comput. Sci..

3-Aminopyrrolidinone farnesyltransferase inhibitors: design of macrocyclic compounds with improved pharmacokinetics and excellent cell potency.

A. D. Rodrigues, J Christopher Culberson, Ronald Robinson, 2002, Journal of medicinal chemistry.

3,8-Diazabicyclo[3.2.1]octan-2-one peptide mimetics: synthesis of a conformationally restricted inhibitor of farnesyltransferase.

M. Bogusky, J. Culberson, C. Dinsmore, 2001, Organic letters.

Conformation of a novel tetrapeptide inhibitor NH2-D-Trp-D-Met-Phe(pCl)-Gla-NH2 bound to farnesyl-protein transferase.

V. Garsky, A. Pessi, M. Bogusky, 1999, The journal of peptide research : official journal of the American Peptide Society.

Comparison of Topological, Shape, and Docking Methods in Virtual Screening

Robert P. Sheridan, Christopher I. Bayly, Vladimir N. Maiorov, 2007, J. Chem. Inf. Model..

Prospective Assessment of Virtual Screening Heuristics Derived Using a Novel Fusion Score

Dante A. Pertusi, Peter S. Kutchukian, Gregory T O'Donnell, 2017, SLAS discovery : advancing life sciences R & D.

Dorsal horn spatial representation of simple cutaneous stimuli.

P. Brown, R. Millecchia, J. Culberson, 1998, Journal of neurophysiology.

Synthesis and Evaluation of 5-Fluoro-2-aryloxazolo[5,4-b]pyridines as β-Amyloid PET Ligands and Identification of MK-3328.

Sandra M. Sanabria-Bohórquez, Scott T. Harrison, E. Hostetler, 2011, ACS medicinal chemistry letters.

Discovery of triarylethanolamine inhibitors of the Kv1.5 potassium channel.

N. Liverton, C. Claiborne, R. Spencer, 2010, Bioorganic & medicinal chemistry letters.

Conformational restriction of flexible ligands guided by the transferred noe experiment: potent macrocyclic inhibitors of farnesyltransferase.

J. Huff, M. Bogusky, S. Graham, 2001, Journal of the American Chemical Society.

Informing the Selection of Screening Hit Series with in Silico Absorption, Distribution, Metabolism, Excretion, and Toxicity Profiles.

Andreas Verras, Robert P Sheridan, J Christopher Culberson, 2017, Journal of medicinal chemistry.

Comparison of Knowledge-Based and Distance Geometry Approaches for Generation of Molecular Conformations

Michael D. Miller, Simon K. Kearsley, J. Christopher Culberson, 2001, J. Chem. Inf. Comput. Sci..

Molecular Transformations as a Way of Finding and Exploiting Consistent Local QSAR

Robert P. Sheridan, Peter Hunt, J. Christopher Culberson, 2006, J. Chem. Inf. Model..

Conformationally constrained o-tolylpiperazine camphorsulfonamide oxytocin antagonists. Structural modifications that provide high receptor affinity and suggest a bioactive conformation.

D. Veber, R. Freidinger, R. Ball, 1994, Bioorganic & medicinal chemistry.

THE SYSTEM FOR NEUROLOGICAL ANALYSIS OF PATIENT SYMPTOMS: AN INTEGRATED ARTIFICIAL INTELLIGENCE PROTOTYPE

Jeffrey L. Sponsler, Frances Van Scoy, James Culberson, 2015 .